These findings align with those of Brauer et al., who emphasized the impact of anthracyclines and HER2 inhibitors on cardiovascular outcomes in BC patients, particularly in BRCA-related genetic vulnerabilities [7]. The gene discussed is ERBB2; the disease is breast cancer.